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The 5T4 oncofoetal antigen is a heavily glycosylated cell surface protein found on human placental trophoblast and on diverse types
of human cancer but is not expressed at significant levels on adult human tissues in health. It therefore satisfies the criteria for a
tumour-associated antigen and is an ideal target for the immunotherapy of cancer. We report here that 5T4 is strongly expressed on
the majority of renal cell carcinomas and therefore this population of patients is suitable for trials of 5T4-targeted therapies. In
particular, we have shown that T cells from renal cell carcinoma patients can be genetically modified to kill 5T4 expressing renal
cancer cell lines by introduction of a chimeric-signalling protein. This protein consists of a single chain antibody fragment capable of
binding antigen directly at the cell surface and then activating the T cell by virtue of a CD3z-signalling domain. This is a powerful tool
that bypasses a number of mechanisms that allow tumours to escape T-cell killing and can be readily scaled up for clinical use.
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Renal cell carcinoma (RCC) makes up around 3% of all adult
malignant tumours in the United Kingdom and is the commonest
neoplasm arising from the kidney (Cancer Registration Statistics,
2001). Approximately a third of patients are cured by surgery while
treatment options for metastatic disease are very limited, as the
cancer tends to be resistant to both chemotherapy and radio-
therapy. Median survival for patients with untreated metastatic
disease is around 12 months (Atzpodien et al, 2003). The only
drugs proven to induce regression of the disease are the
immunomodulatory agents interferon-a (MRC Renal Cancer
Collaborators, 1999) and interleukin-2 (IL-2) (Yang et al, 2003).
Response rates with these agents are low, in the order of 14–20%
and, although a survival advantage has been demonstrated for
interferon-a over hormonal therapy alone, no clear survival
advantage has been demonstrated for IL-2.
Central to the development of better biological therapy for RCC
is the need to identify aberrant or overexpressed proteins that may
distinguish the tumour from normal tissues. These proteins can
then be targeted by a variety of therapeutic strategies such as
monoclonal antibodies (Mab), vaccines or adoptive transfer of
antigen specific T cells. The goal of these approaches is that the
tumour is recognised by the immune system and then eliminated
by cytotoxic effector cells. To date only a small number of
aberrantly expressed proteins have been associated with RCC.
Some of these, such as G250, are cell surface proteins that have
been identified by murine Mab (Oosterwijk et al, 1986). Clinical
trials are already underway utilising a number of immuno-
therapeutic modalities targeting the G250 protein in RCC (Lamers
et al, 2002; Bleumer et al, 2004).
A number of oncofoetal antigens have now been identified that
are expressed in foetal tissues and also by certain malignancies.
5T4 is a 72kDa glycoprotein identified by a murine monoclonal
antibody produced by a hybridoma from splenocytes of mice
immunised with syncytiotrophoblast microvillous membrane
glycoproteins (Hole and Stern, 1988). It is highly expressed on
placental trophoblast and a variety of human cancers (Southall
et al, 1990). Transduction of the 5T4 cDNA into cell lines enhances
cell motility and reduces cell–cell contacts suggesting that it may
be mechanistically involved in the malignant phenotype (Carsberg
et al, 1996). This is further supported by evidence that expression
of 5T4 correlates with poorer survival in colorectal carcinoma
(Starzynska et al, 1994). This protein has only limited expression
in normal adult human tissues (Southall et al, 1990) making it a
useful target for the immunotherapy of cancer.
The most successful targeted approach to immunotherapy
undoubtedly has been the use of monoclonal antibody therapy,
notably in breast cancer (trastuzumab) (Cobleigh et al, 1999) and
non-Hodgkin’s lymphoma (rituximab) (Czuczman et al, 2005).
Once bound to their respective target, Mab’s induce antitumour
activity by one of three principle mechanisms: antibody-dependent
cell-mediated cytotoxicity (Clynes et al, 2000), interruption of
aberrant cell-signalling proteins (Le et al, 2000) or delivery of a
cytotoxic moiety such as a drug, radioisotope or toxin to the
tumour (Wiseman et al, 2002). Antibody therapy does, however,
have a number of limitations such as poor penetration into
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stumour, selection of apoptosis-resistant tumour clones and
inactivation of Mab by serum proteins (Reilly et al, 1995; Jain,
1999). Other strategies for generating an effective immune
response against solid tumours such as vaccination and adoptive
transfer of antigen-specific T cells are therefore being actively
developed.
T cells are one of the key effector cells in a host response to a
tumour (Finn and Lotze, 2001), but by the time a cancer has
become established, it may have evolved strategies to evade T-cell
killing. These include the downregulation of major histocompati-
bilty complex (MHC) molecules and associated transporter
proteins thus preventing antigen presentation of endogenous
peptides (Garrido et al, 1997) and induction of tolerance in T cells
with specificity for tumour-borne epitopes (Mapara and Sykes,
2004). Nevertheless, tumour antigen-specific lymphocytes have
been isolated from tumour-infiltrating lymphocytes (TILs) of
malignant melanoma (Dudley et al, 2002) and these cells were able
to reject tumour upon reinfusion following lymphodepleting
chemotherapy. It has proved much harder to isolate such cells
from RCC tumours (Yannelli et al, 1996) and the few studies using
adoptive cell transfer are yet to yield any encouraging results
(Goedegebuure et al, 1995; Figlin et al, 1999; Dillman et al, 2004).
It may therefore be desirable to evaluate other methods of
making T cells that can recognise renal cell cancer. T cells can be
genetically modified in vitro to possess Mab specificity for a
protein epitope by retroviral transduction with a chimeric T-cell
receptor (Thistlethwaite et al, 2005). This circumvents the natural
process of T-cell activation through MHC and means that a large
polyclonal pool of T cells can be conferred with specificity for one
single antigen. We have previously demonstrated that T cells from
patients with colorectal cancer can kill CEA-expressing cell lines
when retrovirally transduced with a chimeric T-cell receptor with
specificity for CEA protein (Sheen et al, 2003). The chimeric T-cell
receptor consists of an extracellular recognition domain compri-
sing a single chain antibody fragment; this is then fused to an
intracellular CD3z-signalling domain found in the wild-type TCR.
Crosslinking of the chimeric TCR with its respective antigen
results in downstream activation of the T cell, which is then able to
effect target cell killing either directly by production of cytotoxic
moieties such as granzyme, perforin and Fas ligand, or indirectly
via production of cytokines important for T-cell killing such as
interferon-g (Darcy et al, 2000).
Our first aim in this study was to evaluate the expression of the
5T4 oncofoetal antigen by immunohistochemistry in freshly
isolated RCC specimens. Secondly, we wished to test its utility as
a target for gene modified T cells taken from patients with RCC.
Using a chimeric T-cell receptor that binds to the 5T4 protein we
have evaluated whether T cells from patients with RCC could be
genetically modified to kill allogeneic 5T4-expressing renal cell
lines.
MATERIALS AND METHODS
All tissue and blood samples were collected from three hospitals in
the South Manchester region. Approval from the local ethical
committee was given prior to sample collection and informed
consent was obtained from each patient at least a day before
surgery. Additionally, five frozen specimens of normal kidney
from donors without malignant disease were obtained from a
biomaterials supplier (Medical Solutions, Nottingham, UK). Speci-
mens were obtained post mortem with donor consent and ethical
approval.
Immunohistochemistry
Tumour samples were taken from either primary or metastatic
disease in patients with RCC (either suspected or confirmed).
Where possible samples of kidney (at a distance of at least 2cm
away from the primary tumour) were also taken and termed
‘normal’ for this study. The histological type and grade of tumour
was assessed by routine haematoxylin and eosin staining of
paraffin-embedded sections.
Tumour and kidney samples were snap frozen and sectioned
using a freezing microtome. A three-stage immunoperoxidase
technique using the EnVision kit (DakoCytomation Ltd, Denmark)
was used to visualise the 5T4 glycoprotein. Immunohistochemical
staining was performed according to the manufacturer’s instruc-
tions. A murine monoclonal antibody specific for 5T4 was used as
a primary antibody (5T4 IgG1 2.2mgml
 1) at a 1 in 1000 dilution.
Production and characterisation of this antibody has previously
been described (Hole and Stern, 1988). A murine IgG1 isotype
control was applied at the same concentration to separate sections
to act as a negative control.
Cell culture
The renal carcinoma cell lines were a kind gift from Dr J Yang
of the National Institutes of Health, Bethesda, MD, USA. They
were cultured as an adherent monolayer in Dulbecco’s Modified
Eagle Medium with 10% foetal calf serum (Gibco BRL, Paisley,
Scotland). T cells were cultured in T-cell media consisting of
RPMI-1640 supplemented with 25mmoll
 1 HEPES, 50mmoll
 1 b-
mercaptoethanol, 200mmoll
 1 L-glutamine, 50IUml
 1 penicillin,
50mgml
 1 streptomycin (all from Sigma, Dorset, UK) and 5%
human AB serum (Promocell, Heidelberg, Germany). Cells were
kept at 371C in a humidified atmosphere containing 95% air and
5%CO2.
Isolation and activation of peripheral blood lymphocytes
In all, 50ml of heparinised blood was taken from patients at the
time of surgery. The mononuclear cell fraction was isolated by
Ficoll-Hypaque (PAA Laboratories, Pasching, Austria) density
centrifugation. The cells were washed twice in RPMI-1640 and
resuspended in T-cell media before depletion of monocytes by
plastic adherence. After 1h the flask was removed and non-
adherent cells were removed and resuspended in T-cell medium
supplemented with 100IUml
 1 of recombinant human IL-2
(Chiron, Amsterdam, The Netherlands) at a concentration of
1 10
6 cellsml
 1 in T-cell media. The cells were then incubated for
3 days in six-well tissue culture plates precoated with anti-CD3
(Orthoclone, NJ, USA) and anti-CD28 (R&D Systems, MN, USA)
Mab. Lymphocytes were then maintained in culture by adding IL-2
every 3–4 days and maintaining cell concentration around 1 10
6
cells.
Retroviral transduction of peripheral blood lymphocytes
The Kat retroviral system (Finer et al, 1994) was used to genetically
modify the isolated lymphocytes by introducing DNA coding for
one of two chimeric T-cell receptors. The retroviral vector
rKat.MFE.CD3z.TDGA.IRES.eGFP (MFE.CD3z) has been pre-
viously described (Gilham et al, 2002) and encodes a chimeric T-
cell receptor specific for CEA. To create a chimeric T-cell receptor
specific for the 5T4 protein, DNA coding for a humanised scFv
derived from the mouse anti-human 5T4 monoclonal antibody,
together with a human Fc antibody spacer region was exchanged
into the above vector. The inclusion of the Fc space was found to
be optimal for targeting gastrointestinal cancers expressing 5T4
(Guest et al, 2005) and was used in this analysis. This construct
5T4.hFc.CD3z.TDGA.IRES.eGFP was abbreviated to 5T4.CD3z.
Transduced lymphocytes coexpressed enhanced green fluorescent
protein to allow identification of this population by flow
cytometry.
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sThe rKat vector was combined with the packaging plasmid pKat
and introduced into the 293T packaging cell line by calcium
phosphate transfection. Virus was harvested at 48 and 72h. The
first viral harvest was timed to coincide with the end of the 3-day
activation period of lymphocytes as described above. Lymphocytes
and viral particles were combined in T-cell medium supplemented
with 4mgml
 1 polybrene and then centrifuged at 1200 g for 3h.
This spin-fection was then repeated the following day after the
second viral harvest.
Flow cytometry
Surface markers of in vitro cultured cells was analysed on a
FACScan (Becton Dickinson, CA, USA) and analysed using
CellQuest software. Cells (2 10
5) were resuspended in phos-
phate-buffered saline supplemented with 2% bovine serum
albumin. Phyco-erythrin-conjugated antibodies were used to stain
for CD3, CD4 and CD8 (all from Becton Dickinson). 5T4 staining
was performed using 1mgml
 1 of murine anti-5T4 followed by
phyco-erythrin-conjugated anti-mouse IgG (Sigma, Dorset, UK).
Chromium release assay
To measure short-term cytotoxicity mediated by T cells a standard
4-h chromium release assay was used. Target cells were incubated
for 1h with 100mCi [
51Cr]sodium chromate, washed three times
in serum-free media before resuspending in T-cell media at a
concentration of 5 10
4 cellsml
 1. A total of 5000 target cells per
well were then plated out with effector cells in triplicates at the
following ratios: 50:1, 25:1, 12.5:1 and 6.25:1. Spontaneous
release was quantified by adding T-cell medium alone to targets
and maximal release by adding 2% Triton to targets. Following 4-h
coculture, supernatants were removed and plated on to Luma
plates (Packard, Berkshire, UK), released radioactivity was
measured using a TopCount plate reader Packard, Berkshire,
UK). Percentage-specific lysis of targets was calculated using the
following formula: (maximal release sample release)/(maximal
release spontaneous release) 100.
interferon-c release by enzyme-linked immunosorbent
assay
Triplicate wells consisting of 1 10
4 RCC cells and 1 10
5
lymphocytes per well in T-cell medium were set up on a 96-well
plate. The cocultures were left for 24h in an incubator at 371C
supplemented with 5% CO2. The supernatants were removed and
interferon-g concentration determined using matched antibody
pairs MAB285 and BAF285 following the protocol defined in the
manufacturer’s instructions (R&D, Oxfordshire, UK).
RESULTS
5T4 expression on RCC biopsies
Using the EnVision kit, a dark brown precipitate was observed
on the specimen if 5T4 was present. Two observers independently
examined the specimens under light microscopy and classified
them into one of these four groups: strongly positive (þþ),
positive (þ), focal staining (þ/ ) or negative ( ) if no staining
was observed. The pattern of staining was also characterised as
either stromal, tumour membranous or tumour cytoplasmic. This
categorisation was used based on the previous patterns of staining
noted in colorectal and gastric carcinomas (Starzynska et al, 1994).
All positive samples however, clearly demonstrated a membranous
staining pattern (Figure 1A) and there was no evidence of stromal
staining on any of the tumour specimens. Tumour samples were
obtained from 20 patients; 18/20 were primary clear cell
carcinomas (Table 1), the remaining two being papillary cell
Figure 1 Strong positive 5T4 expression in renal cell carcinoma. Light
microscopy ( 20 magnification) of a Fuhrman grade 3 clear cell carcinoma
(A) following application of murine anti-human 5T4 followed by
immunoperoxidase (brown precipitate denoting presence of bound murine
antibody) and haematoxylin stains. The inset picture shows the same tissue
with a mouse isotype control antibody applied. All malignant tissue
examined that stained positive for 5T4 exhibited a membranous staining
pattern. A section of kidney taken from the same patient is demonstrated
(B) showing brown staining within a swollen glomerulus. A sample of tissue
from a normal kidney taken from a donor with nonmalignant disease (C)
was also obtained and this shows much weaker stromal staining within the
glomerulus.
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scarcinomas. 19/20 (95%) samples were at least focally positive for
5T4 and 15/20 (75%) exhibited strong positive staining. From five
patients, samples of ‘normal’ kidney at least 2cm from the
resection margin were taken at nephrectomy. Four of the five
samples demonstrated strong positive glomerular staining
(Figure 1B) while the remaining sample exhibited some focal
tubular staining. However, haematoxylin and eosin staining
showed an inflammatory infiltrate in all of these specimens and
glomerulosclerosis was present in two. The possibility that antigen
shedding from the tumour with subsequent deposition in the
Bowman’s capsule prompted us to evaluate specimens from
donors without malignant disease. We examined five samples of
normal kidney taken from post mortem specimens. All five
demonstrated a weak focal glomerular staining and this was
notably less than that seen in the RCC patient ‘normal’ kidney.
5T4 expression on RCC lines
The renal cell lines 2220R, 2245R, 2246R where trypsinised and
washed twice in serum-free DMEM. 5T4 expression was evaluated
by applying the murine antibody or isotype control and then a
secondary phycoerythrin-labelled anti-mouse IgG antibody. All
cell lines demonstrated clear expression of 5T4 (Figure 2).
5T4.CD3f transduced lymphocytes demonstrate enhanced
killing and interferon-c release when in contact with renal
cell lines
Peripheral blood lymphocytes from three patients with RCC were
activated on anti-CD3/anti-CD28-coated tissue culture plates as
described above. For each patient, a third of the activated T cells
underwent a mock transduction with no retrovirus; this population
would be used as a negative control to determine background
levels of cytotoxicity and cytokine release. A third of the activated
lymphocytes were transduced with the MFE.CD3z construct and
the remaining third transduced with the 5T4.CD3z construct. The
RCC cell lines did not express CEA (data not shown) and therefore
the purpose of using T cells transduced with the MFE.CD3z
construct was to demonstrate that killing and cytokine release was
dependent on the specificity of the 5T4.CD3z chimeric receptor.
We have previously shown the specificity of this receptor for
human 5T4 expressed in mouse cell lines (Guest et al, 2005). At 3
days prior to performing any of these assays, the IL-2 concentra-
tion in the T-cell cultures was reduced to 20IUml
 1 to reduce any
background lymphocyte-activated killer (LAK) activity. All assays
were performed within 3 weeks of initial transduction.
Prior to each assay being performed, the lymphocyte popula-
tions were analysed by flow cytometry. All lymphocyte populations
were 492% CD3þve indicating they were predominantly T cells
(Table 2). In patients 4, 11 and 14 the transduction levels of
MFE.CD3z were 43, 38 and 24%, respectively. However, the values
for 5T4.CD3z were significantly lower for each patient at 22, 15
and 13%, respectively (Table 2). We have routinely found that
efficiency of expression of the 5T4.CD3z construct is approxi-
mately half the level of the MFE.CD3z construct although the
Table 1 Patient characteristics and 5T4 expression
Sex Age Nature of specimen Histology Fuhrman grade TNM stage Pattern of 5T4 staining
F 67 Primary renal Papillary 2 T2N0M0 ++
M 67 Primary renal Papillary 2 T1bN0M0 ++
M 70 Primary renal Clear cell 2 T3aN0M0 +/ 
F 53 Primary renal Clear cell 3 T3aN0M0  
F 67 Primary renal Clear cell 3 T3aN0M0 ++
F 48 Primary renal Clear cell 2 T1aN0M0 +
F 68 Primary renal Clear cell 2 T1bN0M0 ++
M 57 Primary renal Clear cell 4 T4N2M1 ++
M 73 Primary renal Clear cell 2 T1bN0M0 ++
M 50 Primary renal Clear cell 1 T1bN0M0 ++
M 49 Primary renal Clear cell 4 T3bN0M0 +
M 75 Primary renal Clear cell 3 T3bN0M0 +/ 
M 64 Primary renal Clear cell 2 T3bN0M0 ++
F 46 Primary renal Clear cell 2 T3aN0M0 ++
F 65 Primary renal Clear cell 3 T3bN0M0 ++
M 64 Primary renal Clear cell 2 T3bN0M0 ++
F 43 Metastasis Clear cell NA TXNXM1 ++
M 66 Metastasis Clear cell NA TXNXM1 ++
M 49 Primary renal Clear cell 3 T1aN0M0 ++
F 51 Primary renal Clear cell 2 T3aN0M0 ++
NA¼not applicable.
Figure 2 5T4 expression in renal cell carcinoma lines. Renal cell
carcinoma cell lines were incubated with murine anti-5T4 antibody or
isotype control and then a secondary PE-labelled anti mouse IgG applied.
The histograms show the FACS results for (A) 2220R, (B) 2245R and (C)
2246R.
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sreason for this is not clear. A 4h chromium release assay was
performed on each of the three RCC lines and in each case, we
observed significantly enhanced killing of the renal cell lines by
5T4.CD3z-transduced lymphocytes when compared to either the
MFE.CD3z transduced or the mock-transduced lymphocytes
(Figure 3). To determine functionality of the modified T cells in
mounting an effective cytokine response, the production of
interferon-g from T cells was assayed when cocultured with target
cells at a ratio of 10:1. Figure 4 demonstrates that the 5T4.CD3z-
transduced T cells were able to generate significantly higher
amounts of interferon-g on contact with 5T4 expressing cell lines
compared to either mock transduced or MFE.CD3z-transduced
T cells. Importantly, the levels of cytotoxicity and interferon-g
release in the mock and MFE.CD3z-transduced cells were similar
indicating that this effect had not occurred as a result of retroviral
transduction.
DISCUSSION
We have demonstrated in twenty RCC specimens that the 5T4
oncofoetal antigen is expressed to high levels in almost all cases of
RCC. Importantly, the strong positive membrane expression on
most of the tumour specimens makes RCC a good candidate for
5T4-targeted therapies. Previous reports of 5T4 have documented
minimal expression on normal tissue (Southall et al, 1990) and we
wished to confirm this was the case with respect to the kidney.
We were able to analyse normal kidney taken greater than 2cm
from the tumour margin in five patients, however, the surrounding
Table 2 Phenotype of transduced lymphocytes
CD3 (%) CD4 (%) CD8 (%) EGFP (%)
Patient 4
Mock 94 50 36 NA
MFE.CD3z 95 50 35 43
5T4.CD3z 92 40 36 22
Patient 11
Mock 98 35 60 NA
MFE.CD3z 99 31 57 38
5T4.CD3z 99 35 58 15
Patient 14
Mock 94 15 68 NA
MFE.CD3z 96 18 64 24
5T4.CD3z 95 22 65 13
NA¼not applicable.
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Figure 3 5T4 targeted T cells efficiently kill 5T4 expressing RCC lines. Lymphocytes from patient 4 were activated, expanded and transduced with either
the MFE.CD3z construct, 5T4.CD3z construct or were subject to a mock transduction. Lymphocyte populations were then cocultured for 4h with
51Cr-labelled RCC cells from cell lines (A) 2220R, (B) 2245R and (C) 2246R. Each point represents a triplicate of wells, each well containing 5000 target
tumour cells. The bars refer to the s.d. for each dilution.
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Figure 4 Interferon-g release. Representative results again from patient
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5 lymphocytes were cocultured for 24h with 1 10
4 RCC
cells from the three cell lines: 2220R, 2245R and 2246R. After 24h the
supernatants were removed and assayed for interferon-g by ELISA. Error
bars refer to the s.d. for each dilution.
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skidney in RCC frequently shows inflammatory change and our
samples were no exception. We observed the presence of 5T4
within the Bowman’s capsule in all five of our ‘normal’ kidney
specimens. In case this result was due to antigen shedding and
glomerular deposition, we also examined five post mortem
specimens from donors who had otherwise healthy kidneys and
no known malignant disease. They also showed some evidence of
focal glomerular 5T4 expression although to a much lesser extent.
It would appear therefore; that there is low-level expression of
5T4 on renal glomeruli and this confirms a previously published
result (Connolly et al, 2003; Valle et al, 2003). A number
of immunological therapies targeting 5T4 are currently undergoing
assessment in phase I and II clinical trials and it should be
noted that in no patients to date has any renal toxicity been
reported. 5T4 has been targeted by a vaccine-based approach:
A gene-modified vaccine has been developed by inserting the
gene for 5T4 into an attenuated vaccinia virus (Trovaxt). In
preclinical murine models a similar construct demonstrated
protection against tumour establishment and activity against
pre-existing tumour (Mulryan et al, 2002). TroVax has been used
clinically in phase I and II trials for patients with metastatic
colorectal cancer and can induce antibody and T-cell responses to
5T4 with no toxicity (Valle et al, 2003). This finding is of relevance
to RCC as this is one of few diseases were positive clinical results
have been observed using a vaccine-based approach. A recent
German trial has demonstrated improved disease free-survival
with an adjuvant tumour cell vaccine in high-risk RCC patients
(Jocham et al, 2004).
Another approach utilising 5T4 involves generation of a
monoclonal antibody immune conjugate. Here, a monoclonal
antibody against 5T4 is linked to a superantigen such as
Staphylococcal enterotoxin B that directly binds the T-cell receptor
in a construct engineered to reduce its MHC class II binding. Thus,
the fusion protein acquires the ability to activate T cells when
binding to the 5T4 target on the tumour cell. Accumulation of this
immune conjugate at the tumour site should then result in local
T-cell recruitment and activation (Connolly et al, 2003).
It has been recognised that the 5T4 antigen is present on a wide
range of tumour types and that its expression can be associated
with a poorer prognosis. In our study, we have insufficient
numbers to correlate the degree of expression to prognosis or
histological grade. Previous studies have shown that the human
5T4 protein when transduced into cell lines reduces cell–cell
contacts and enhances cell motility, suggesting it may play a role in
supporting tumour invasion and metastasis (Carsberg et al, 1995,
1996). The remarkable finding in this study is the consistency of
high expression levels of 5T4 in RCC and it is therefore tempting to
speculate whether this may be linked to other proteins expressed
to high levels in RCC. A frequent finding in the majority of
conventional clear cell carcinomas is a mutation in the von
Hippel-Lindau (VHL) suppressor gene (Ma et al, 2001), the protein
product of this gene is required for degradation of hypoxia-
inducible factor 1a (HIF-1a). Tumour hypoxia and VHL gene
mutations in RCC lead to accumulation of HIF-1a (Wiesener et al,
2001), this protein then leads to transcription of a number of genes
which predominantly affect angiogenesis and assist in tumour
expansion. The human 5T4 promoter sequence has been examined
and does not appear to contain any sequences that are now known
to be HIF-1a responsive (Myers et al, 1994), but this is an area
which needs further exploration, particularly because HIF-1a is
instrumental in mediating early trophoblast differentiation. Our
main interest in this protein, however, is that it represents a useful
tumour antigen in that it is expressed strongly at the cell surface in
RCC tumours and minimally in normal tissues. We did observe
focal glomerular staining within surrounding kidney in one of
the five patients from whom normal tissue could be obtained.
We therefore propose that because of the consistent expression of
this protein in RCC and the sensitivity of this tumour to immuno-
logical therapies, future trials of 5T4-targeted agents could
particularly focus on this population of cancer patients.
The use of adoptively transferred T cells as a therapy for solid
tumours is still in its infancy, with one of the main barriers to the
technique being the ability to generate large numbers of tumour
antigen-specific lymphocytes. Large numbers of tumour reactive
lymphocytes isolated from naturally occurring TIL populations
have been used for the treatment of melanoma and clinical
responses have been observed in patients who had already failed
multiple lines of conventional therapy (Dudley et al, 2002).
However, in one case report, resistance to treatment occurred as
a result of the therapy selecting out tumour cells which lack MHC I
expression (Khong et al, 2004). Isolation of tumour-specific
clones of T cells is possible with melanoma because of common
presence of skin metastases and identification of common T-cell
antigens; obtaining and expanding such cells from other solid
tumours has been more difficult. The ability to engineer T cells
from the peripheral blood and confer on them antibody-
type specificity without the need for MHC presentation of antigen
by tumour represents an important step forward in bypassing
some of the barriers to effective T-cell therapy. This modality is
also likely to have a number of advantages over conventional
monoclonal antibody therapy in that T cells have discrete
homing and tissue penetration capabilities together with the
ability to effect immediate target cell death on activation via
their T-cell receptor. As a result of the potency of the T-cell
response, one major concern is that of reactivity against normal
host cells that also express the protein that is being targeted.
Evidence to date suggests that 5T4 is expressed at low levels in
normal subjects but a carefully planned phase I study is now
appropriate.
Adoptive T-cell therapy is of particular relevance to RCC given
the sensitivity of this tumour to immunomodulatory drugs. The
ability to generate 5T4-specific T cells ex vivo represents an
important advance in bringing this modality of treatment into
the clinic. Before this technique is scaled up for clinical use, there
remain issues yet to be resolved. Firstly, the 5T4.CD3z construct
has a comparatively poor transduction efficiency using the Kat
retrovirus as described, and this needs to be optimised. Secondly,
the optimal method of expanding T cells for transduction is still
being debated. We routinely use IL-2 to expand T cells, but
evidence is emerging that this may also assist in the expansion of
regulatory T cells, this subpopulation may be impeding some of
the observed cytotoxicity that we are engineering in to these cells
(Nelson, 2004). There may be advantages in using different
cytokines such as IL-7 and IL-15 to grow cytotoxic T cells (Antony
and Restifo, 2005), or alternatively magnetically depleting reg-
ulatory cells from the precursor population. Another development
in the field of T-cell expansion is the use of T-cell expansion beads
coated with antibodies to CD2, CD3 and CD28 (Dudley, 2003).
These appear to provide more reliable and rapid expansion of
T cells and may therefore improve transduction efficiency and
also generate higher numbers of cells that are needed for adoptive
transfer.
In conclusion, we have shown that polyclonal lymphocytes taken
from the peripheral blood can be directed against the 5T4 protein
strongly expressed on the vast majority of RCCs. This method
could lead to an effective approach for the cellular therapy of this
notoriously difficult disease.
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